Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences Co., Ltd. has received approval from the National Medical Products Administration for two supplemental new drug applications for its ongericimab injection, a PCSK9-targeted monoclonal antibody. This approval marks the first domestic PCSK9-targeted drug for statin-intolerant patients in China, potentially enhancing the company’s market position in the cardiovascular treatment sector. The approval is based on successful Phase III clinical trials demonstrating significant reductions in LDL-C levels, which is crucial for managing cardiovascular disease risk.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a pharmaceutical company in China, focusing on the development and production of innovative drugs. The company specializes in biologics, particularly monoclonal antibodies, targeting various diseases including hypercholesterolemia.
Average Trading Volume: 2,579,547
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.26B
See more data about 1877 stock on TipRanks’ Stock Analysis page.